Categories
Archives
Receive Email Updates

-


-
Certified Licensing Professionals, Inc., 2021 Disclaimer
This blog, Patents4Life, does not contain legal advice and is for informational purposes only. Its publication does not create an attorney-client relationship nor is it a solicitation for business. This is the personal blog of Warren Woessner and does not reflect the views of Schwegman Lundberg & Woessner, or any of its attorneys or staff. To the best of his ability, the Author provides current and accurate information at the time of each post, however, readers should check for current information and accuracy.
- About Me

Warren D. Woessner
Pages
Archives
Tag Archives: Federal Circuit
ABBOTT LABS. v. SANDOZ, INC. – ONE RULE FITS ALL?
Or “what’s sauce for the goose is sauce for the gander”? Posts and pens have been busy reporting that the Federal Circuit, en banc, overruled Scripps v. Genentech, and ended the debate over whether a product-by-process claims should be construed … Continue reading
Ariad: “The Future Ain’t What It Used To Be!” Judge Linn’s Concurrence and the Abuse and Neglect of the Enablement Requirement at the Federal Circuit
In my post of April 13, 2009, I concluded with a brief summary of Judge Linn’s cogent concurrence, and noted that I would revisit it. Judge Linn does not believe that it was ever necessary for the court to graft … Continue reading
Patent Office Bats Down Ariad’s ‘Hail Mary Claims’ In Reexamination
In my earlier post on Ariad v Lilly, there is a detailed discussion of the Federal Circuit’s recent decision that invalidated all of the claims-in-suit for failure to meet the written description requirement. The Federal Circuit rejected Lilly’s attempts to … Continue reading
Posted in Patent Eligible Subject Matter
Tagged Ariad, biotechnology, Eli Lilly, Federal Circuit, intellectual property, ip, USPTO, valiente
Leave a comment
